Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02984124 · ClinicalTrials.gov registry record · Phase 2
Communication During Hospitalization About Resuscitation Trial
A Phase 2 study of End Stage Renal Disease and Severe Life-limiting COPD, sponsored by University of Vermont.
- Active
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
- 4
- Study locations
NCT02984124 is a Phase 2 study of End Stage Renal Disease and Severe Life-limiting COPD that is active but no longer recruiting, run by University of Vermont. The registered enrollment target is 182 participants, below the 831-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (78% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02984124, a Phase 2 study of End Stage Renal Disease and Severe Life-limiting COPD, is active but no longer recruiting, sponsored by University of Vermont.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
- 4
- Study locations
Study Summary
This multicenter RCT of 200 hospitalized patients and their family members evaluates an "informed assent" approach to discussing cardiopulmonary resuscitation, compared to usual care, in older seriously ill hospitalized patients with severe life-limiting illness or severe functional impairment.
Conditions Studied
Interventions
- BEHAVIORAL Informed Assent Discussion
- BEHAVIORAL Usual Care with Attention Control
Study Locations (4)
North Carolina
- University of North Carolina - Chapel Hill
South Carolina
- Medical University of South Carolina - Charleston
Vermont
- University of Vermont - Burlington
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2016-12 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02984124
The ClinicalTrials.gov registry entry for NCT02984124 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 831-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (78% lower). The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which Informed Assent Discussion is the first listed.
NCT02984124 reports 4 study locations spanning 4 distinct geographic areas - top geographies include North Carolina, South Carolina, Vermont.
Frequently Asked Questions
What is clinical trial NCT02984124 about?
NCT02984124 is a clinical study titled "Communication During Hospitalization About Resuscitation Trial". This multicenter RCT of 200 hospitalized patients and their family members evaluates an "informed assent" approach to discussing cardiopulmonary resuscitation, compared to usual care, in older seriously ill hospitalized patients with severe life-limiting illness or severe functional impairment.
What is the current status of trial NCT02984124?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2016-12. Estimated completion is 2025-12.
What conditions does trial NCT02984124 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Severe Life-limiting COPD, Severe Life-limiting Heart Failure, Severe Life-limiting Cirrhosis, Severe Life-limiting Malignancy.
What interventions are being tested in trial NCT02984124?
The interventions under investigation include: Informed Assent Discussion (BEHAVIORAL), Usual Care with Attention Control (BEHAVIORAL).
Who is sponsoring clinical trial NCT02984124?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02984124 being conducted?
This trial has 4 study locations across North Carolina, South Carolina, Vermont, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
-
Safety and Efficacy of Empagliflozin in Hemodialysis
RECRUITING · Phase 2
-
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
RECRUITING · Phase 2
-
The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients
COMPLETED · Phase 2
-
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
COMPLETED · Phase 2
-
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
COMPLETED · Phase 2
Explore more on PlainTrial
End Stage Renal Disease
All registered trials for this condition
Severe Life-limiting COPD
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.